Oseltamivir-resistant influenza A(H1N1)pdm09 virus in Dutch travellers returning from Spain, August 2012

A Meijer1, M Jonges, P van Beek

  • 1Laboratory for Infectious Diseases and Screening, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands. adam.meijer@rivm.nl

Insights

Two Dutch travellers contracted oseltamivir-resistant influenza A(H1N1)pdm09 virus infections. The neuraminidase H275Y substitution suggests potential for widespread emergence of resistant strains.

Area of Science:

  • Virology
  • Epidemiology
  • Antimicrobial Resistance

Background:

  • Influenza A(H1N1)pdm09 is a significant human pathogen.
  • Oseltamivir is a key antiviral medication used for influenza treatment.
  • Neuraminidase inhibitors are crucial for managing influenza outbreaks.

Observation:

  • Two unrelated Dutch travellers were diagnosed with oseltamivir-resistant influenza A(H1N1)pdm09 in August 2012.
  • Infections were likely acquired during separate holidays on the Catalonian coast, Spain.
  • No prior oseltamivir treatment or epidemiological link was identified between the cases.

Findings:

  • Genetic analysis identified the H275Y substitution in the neuraminidase gene, conferring oseltamivir resistance.
  • Permissive mutations were also detected, potentially facilitating the emergence and spread of resistant strains.
  • This indicates a spontaneous emergence of resistant influenza strains independent of patient treatment.

Implications:

  • The findings highlight the potential for rapid evolution of antiviral resistance in influenza viruses.
  • This underscores the need for continuous surveillance of drug-resistant influenza strains.
  • Public health strategies may need to adapt to the growing threat of oseltamivir-resistant influenza.